World Library  
Flag as Inappropriate
Email this Article

Shire Plc

Article Id: WHEBN0017705425
Reproduction Date:

Title: Shire Plc  
Author: World Heritage Encyclopedia
Language: English
Subject: List of companies of Ireland
Publisher: World Heritage Encyclopedia

Shire Plc

For other uses, see Shire (disambiguation).
Shire Plc
Public limited company
Traded as ,
Industry Pharmaceuticals
Predecessor(s) Shire Pharmaceuticals Group Plc
Founded 1986
Headquarters Registered Office: St Helier, Jersey
Corporate HQ: Dublin, Ireland
UK Operations: Basingstoke, England
Key people Matthew Emmens (Chairman)
Flemming Ornskov, MD (CEO)
Revenue $4,681.2 million (2012)[1]
Operating income $949.2 million (2012)[1]
Net income $745.4 million (2012)[1]
Employees 5,367 (2012)[2]

Shire Plc is a Jersey-registered, Irish-headquartered global speciality biopharmaceutical company that is the manufacturer of pharmaceuticals.[3] Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft.

Shire has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £11.1 billion as of 26 April 2013, making it the 37th-largest company on the London Stock Exchange.[4] Shire has a secondary listing on NASDAQ.


Shire was founded by Harry Stratford, Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall in 1986.[5] It was first listed on the London Stock Exchange in 1996.[5] Shire's initial products were calcium supplements for patients seeking to treat or prevent osteoporosis. Shire's acquisitions include:

  • Pharmavene in 1997[6]
  • Richwood Pharmaceutical Company in 1997, which formed Shire-Richwood, Inc.[7]
  • Biochem Canada in 2001[8]
  • Transkaryotic Therapeutics (now Shire Human Genetic Therapies) in 2005[9]
  • New River Pharmaceuticals Inc, owners of Vyvanse, for $2.3bn in 2007[10]
  • Jerini, a German company focusing on hereditary angioedema (HAE), in 2008[11]
  • Movetis, a Belgian company focusing on gastrointestinal products, in 2010[12]
  • Advanced BioHealing, a regenerative medicine company, in 2011[13]
  • FerroKin BioSciences, a privately held biotechnology firm, in 2012[14]
  • Lotus Tissue Repair, Inc., a privately held biotechnology company, in 2013[15]
  • Premacure AB, a privately held biotechnology company, in 2013[16]
  • SARcode Bioscience Inc., a privately held biopharmaceutical company, in 2013[17]


Shire develops and provides healthcare in the areas of behavioural health, gastrointestinal conditions, rare diseases, and regenerative medicine.


Name Annual revenue[1] Indication
Vyvanse $1,029.8M Attention Deficit Hyperactivity Disorder (ADHD)
Adderall XR $429.0M Attention Deficit Hyperactivity Disorder (ADHD)
Replagal $497.5M Fabry disease (lysosomal storage disorder)
Elaprase $497.6M Hunter syndrome (lysosomal storage disorder)
Lialda/Mezavant $399.9M Gastrointestinal (Ulcerative colitis)
VPRIV $306.6M Type 1 Gaucher disease
Pentasa $265.8M Gastrointestinal (Ulcerative colitis)
Intuniv $287.8M Attention Deficit Hyperactivity Disorder (ADHD)
Fosrenol $172.0M Renal disease
Dermagraft $153.8M Diabetic Foot Ulcers (“DFU”)
Firazyr $116.3M (Hereditary angioedema)
Other $250.6M

Royalty income

Name Annual revenue[1] Indication Licensee
Adderall XR $70.3M Attention Deficit Hyperactivity Disorder (ADHD) Imapx and Teva
3TC (Lamivudine) and Zeffix (Lamivudine) $91.6M HIV and Chronic hepatitis B GlaxoSmithKline
Fosrenol $53.3M Renal disease Bayer Yakuhin
Other $26.4M


The original corporate head quarters and still major operation base are located in Basingstoke, Hampshire, England. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Lexington, Massachusetts and San Diego, California.

Tax Avoidance

In 2008, in reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.[18] Effected through the creation of a new holding company in St Helier, Jersey in the Channel Islands, it will pay reduced tax on global earnings, where royalties on patents lodged in Ireland are tax free.

Corporate leadership

The non-executive Board chairman is Matthew Emmens. Flemming Ornskov, MD, chief executive officer. Graham Hetherington, chief financial officer.

See also


External links

Companies portal
  • Official site
  • German pharmaceutical branch
  • Yahoo profile

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.